过去一年中添加的文章，按日期排序
[HTML][HTML] Antiplatelet Treatment With Dual Pathway Inhibition: A Pathway of Consistency?
T Geisler - European Cardiology Review, 2024 - ncbi.nlm.nih.gov
82 天前 - … cardiovascular events (MACE) with DPI compared with aspirin alone, with an
overall risk … The restriction to aspirin as the antiplatelet and rivaroxaban as the anticoagulant …
overall risk … The restriction to aspirin as the antiplatelet and rivaroxaban as the anticoagulant …
[HTML][HTML] Efficacy and safety of drugs in residual cardiovascular risk: a systematic review of the literature
MA Hernandez-Sómerson, F Montoya-Agudelo… - … Cardiovascular Risk and …, 2024 - Elsevier
98 天前 - … MACE in subjects with stable coronary artery disease. … reduced events in patients
with stable coronary artery disease and … Among patients with stable cardiovascular disease, …
with stable coronary artery disease and … Among patients with stable cardiovascular disease, …
[HTML][HTML] Rivaroxaban plus aspirin, lowers CV and major adverse limb events, but increases bleeding in patients with stable CAD and PAD
114 天前 - … of patients with stable coronary artery disease (CAD) and peripheral artery disease
(PAD). The factor Xa inhibitor apixaban, in combination with antiplatelet therapy, showed …
(PAD). The factor Xa inhibitor apixaban, in combination with antiplatelet therapy, showed …
Perioperative management and outcomes in patients receiving low-dose rivaroxaban and/or aspirin: a subanalysis of the Cardiovascular Outcomes for People Using …
JD Douketis, Q Yi, DL Bhatt, E Muehlhofer… - … of Thrombosis and …, 2024 - Elsevier
136 天前 - … and clinical outcomes associated with combined rivaroxaban-ASA is important
because a large number of patients with cardiovascular disease are eligible to receive this …
because a large number of patients with cardiovascular disease are eligible to receive this …
Non-compaction Cardiomyopathy: A Rare Cause of Embolic Stroke in a Middle-aged Woman
M Duchow, G White, A Benchakroun… - C43. BRAIN-STORMS …, 2024 - atsjournals.org
143 天前 - … The patient was subsequently started on rivaroxaban and optimized on GDMT
for HF. She remained stable and was discharged on day 8. Discussion: The clinical …
for HF. She remained stable and was discharged on day 8. Discussion: The clinical …
Oral anticoagulants and antiplatelet treatment in different settings
S Agewall - European Heart Journal-Cardiovascular …, 2024 - academic.oup.com
172 天前 - … when comparing apixaban to dabigatran and rivaroxaban among patients with
eGFR 30–49 mL/min/1.73 m Although cardiovascular diseases are the leading cause of death …
eGFR 30–49 mL/min/1.73 m Although cardiovascular diseases are the leading cause of death …
[HTML][HTML] Inhibitory effect of rivaroxaban on protease-activated receptor-2 in circulating neutrophils among patients with atrial fibrillation
M Nakano, S Yasuda, Y Hasebe… - … of Cardiology. Heart …, 2024 - ncbi.nlm.nih.gov
184 天前 - … mg twice daily, in reducing thrombotic events and all-cause mortality … stable
coronary artery disease (CAD) patients, the addition of low-dose rivaroxaban to acetylsalicylic acid …
coronary artery disease (CAD) patients, the addition of low-dose rivaroxaban to acetylsalicylic acid …
[引用][C] Simulated Impact of Double Antithrombotic Therapy in White and Non-White Patients With Stable Peripheral, Cerebrovascular and/or Coronary Artery Disease
CRB Neves, ZS Reges, IB Casella, HB Neto… - Journal of Vascular …, 2024 - jvascsurg.org
185 天前 - … DAT appears to have a good risk-benefit for patients with stable cardiovascular
disease of all ethnic groups. Non-white individuals appeared to present a better safety profile for …
disease of all ethnic groups. Non-white individuals appeared to present a better safety profile for …
INVESTIGATING THE SAFETY AND EFFICACY OF ANTIEPILEPTIC DRUGS: DRUG-DRUG INTERACTIONS IN A PATIENT WITH MULTIPLE COMORBIDITIES.
AK Feinweber, EA Dho-Nagy - Acta Marisiensis. Seria …, 2024 - search.ebscohost.com
261 天前 - … Additionally, he is diagnosed with grade II hypertension, chronic ischemic heart
disease, New York Heart Association (NYHA) Class III/IV heart failure, a history of myocardial …
disease, New York Heart Association (NYHA) Class III/IV heart failure, a history of myocardial …